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need for political unity, substantial financial investments, and adaptability when 
faced with obstacles and suboptimal results.
PHP187
THe FuTure oF educaTion in HTa and HealTH economics
Carroll C., Beecroft C., Miller L.
The University of Sheffield, Sheffield, UK
Objectives: An increasing range of online education is available to those working 
in the field of pharmaco-economics and Health Technology Assessment (HTA). The 
aim of this study was to explore the market for free online education in HTA and to 
assess the practicalities of delivering a free, interactive short-course. MethOds: 
We delivered a 5-week online course at the end of 2013 following the princi-
ples of the Massive Open Online Course (MOOC) approach: the HTA MOOC. The 
programme covered the basics of HTA: What it is; how new technologies are 
identified; how they are evaluated; the principal means of assessing clinical and 
cost-effectiveness; and how HTA is used within different health systems to inform 
reimbursement decisions. The course was provided through the Coursesites, a free, 
open-access, education platform. Materials were adapted from an existing online 
MSc programme. Descriptive statistics of participants were recorded and a survey 
conducted of participants’ experiences. Results: 2039 individuals registered for 
the HTA MOOC, of which 1508 completed a voluntary survey giving basic socio-
demographic data about themselves. Participants were from Europe (55%), Asia 
(16%) and North America (13%) and accessed the MOOC to gain knowledge about 
the subject (78%), and specifically for career development (56%). 531/2039 (26%) 
of those registered in Week 1 completed the MOOC (i.e. submitted all required 
weekly assessments by the end of Week 5), compared to an average of 5-6% for 
MOOCs generally [THES 2013]. Students reported the principal strength of the 
programme to be the quality and usefulness of the learning materials, and the 
principal issue to be time required (workload was considered by some to exceed 
the 4-5 hours/week intended). cOnclusiOns: The MOOC approach offers scope 
for delivering flexible, effective and accessible education to small or large inter-
national cohorts of professionals, patients and providers working within HTA and 
pharmaco-economics.
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PHarmacoeconomic educaTion in Brazilian scHools oF PHarmacy
Freitas G.1, Balbinotto G.2
1UFRGS, Porto Alegre, Brazil, 2Universidade Federal Do Rio Grande Do Sul, PORTO ALEGRE, Brazil
Objectives: The objective of this study was to survey the pharmacy schools in 
Brazil to determine the extent of education in pharmacoeconomics offered during 
the school year 2012-2013. MethOds: A questionnaire based on previous studies 
was developed. This was emailed to 55 pharmacy schools in Brazil during October 
and December 2013. The schools were selected from the Ministry of Education 
website. Public and private University schools (only those that have high concepts 
in the National Examination Performance of Students) were included. In addition, 
a search was made in the database directories of research groups from National 
Council for Scientific and Technological Development (CNPq). Results: Of the 55 
questionnaires sent, 16 were returned (29%). Only two schools do not address the 
education of pharmacoeconomics in any moment. Most of schools address some 
concepts in different subjects (8 hours). Five schools have formal courses that 
teach only pharmacoeconomics and health technology assessment (over 30 hours). 
All agree that the education of pharmacoeconomics is important and ten schools 
believe that very few hours are devoted to the teaching pharmacoeconomics at 
his university. In search of directories of research groups 23 groups that develop 
research in the area of pharmacoeconomics in Brazil were found. cOnclusiOns: 
There is a large deficit in the availability of courses pharmacoeconomics in Brazil 
at both the undergraduate and graduate. There is a great opportunity for expe-
rienced individuals to fill this gap. Provide an education in pharmacoeconomics 
for pharmacy students is especially important in the context of evidence-based 
decisions and when health issues and allocation of scarce resources is a priority 
for Brazil.
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aPPlicaTion oF a ‘nice PosT-Hoc B/s analysis’ To THe nice aPPraisal 
Process
Macaulay R.
HERON Commercialization, London, UK
Objectives: Post-hoc subgroup analyses are still used in clinical trials of medi-
cal technologies to identify patient populations in whom greatest benefits can 
be achieved, despite this being derided as an analytical approach. Indeed, using 
such an approach, aspirin has been shown to be ineffective versus placebo in 
acute myocardial infarction patients born under the star signs of Libra and Gemini 
(ISIS-2, 1988, Lancet) and endarterectomy is only efficacious in treating sympto-
matic stenosis patients born on a Monday, Wednesday, or Friday (ECST group, 1998, 
Lancet). This research aimed to determine what effect the name of a drug has 
on the National Institute of Health and Care Excellence (NICE) appraisal process 
by applying a post-hoc analysis that compares the rates of acceptance by the 
first letter of the drug or technology name using a Chi-squared test. MethOds: 
All final appraisal determinations resulting from Single Technology Appraisal 
(STA) or Multiple Technology Appraisal (MTA) processes were identified up 
to April 2014 from which the first letter of the generic name and the decision 
were extracted. Results: 481 appraisals were identified, 371 (77%) of which 
were approved (defined as ‘recommended’ or ‘optimised’), spanning all letters 
of the alphabet except J, K, W, X, and Y. The lowest approval rates by letter were 
for B (64%, 14/22) and S (69%, 18/26). Drugs beginning with a B or S were sig-
nificantly less likely to be approved than drugs beginning with any other letter 
(p= 0.0072). cOnclusiOns: Based on this ‘NICE post-hoc B/S analysis,’ manufac-
turers should consider lobbying the World Health Organization to give their new 
pharmaceuticals International Nonproprietary Names beginning with ‘B’ or ‘S’ 
to optimise success rates in the NICE appraisal process. Alternatively, regulators 
and HTA bodies should continue to view efficacy claims on the basis of post-hoc 
sub-group analyses with great scepticism.
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imPacT oF sTory Books on PromoTing knowledge and BeHavior oF 
4TH sTage elemenTary sTudenTs aBouT raTional use oF medicines in 
kermansHaH Provine oF iran 2008
Mohammadhosseini N.
National Committee on Rational Drug Use, Tehran, Iran
Objectives: Evaluation of the impact of children stories on promotion 
of the knowledge and behavior of 4th stage elementary students about 
rational use of medicines in the Kermanshah elementary schools. MethOds: 
64 elementary schools were selected in Kermanshah province of Iran. The 
schools were categorized into 3 groups (rich, medium and poor level) based on 
their students’ economic level. Both boys and girls were involved. Two checklists 
were designed in order to evaluate students’ knowledge and behavior before 
and after the intervention. A story book which was published by National 
Committee of Rational Drug Use (RUD) conveyed to the students as the inter-
vention. Results:  The correlation between pre and post intervention and the 
schools economic levels and the gender of students were obtained. The knowl-
edge change rates were 21.83%, 22.28% and 17.40% for rich, medium and poor 
schools respectively. The change rate for girls was greater in comparison to 
that of boys. cOnclusiOns: It is concluded that children stories as an educa-
tional intervention causes valuable positive changes on students’ knowledge 
and behavior regarding hygiene and medicine. Implementing such interven-
tions among children, result in promoting rational use of medicines in future 
of the society.
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clinical Trials in France: an underexPloiTed oPPorTuniTy
Mahi L., Mahi I.
Axelys Sante Affaires Medicales et Recherche Clinique, Paris, France
Objectives: Despite high-performance infrastructures and recognized 
expertise, Clinical trials (CT) are declining in France. Health Professionals 
deplore the burdens of the French administration that leads to a real concern 
regarding the international scientific competition. In addition patients are reluc-
tant to participate in CT especially after the benfluorex scandale. MethOds: One 
of the witnesses of the competitiveness of France in CT is the activities among 
Clinical Investigation Centers (CIC). These are plateforms fully dedicated to clini-
cal and scientific research acting as an interface between INSERM units (Public 
National Institut of Scientific Research) and CHU (University Hospital). Results: 
There are 54 CIC in France. They have been created between 1992 and 2009. CICs 
are located in university hospitals (CHU) dessiminated in the most important 
regions of the country. The specific needs of CHU and researchers have led to 
implement several types of CICs: multi-topics (24 CIC-P), Clinical Epidemiology 
(9 CIC-EC), integrated in biotherapy (11 CIC-BT) and technological innovations (8 
CIC-IT). During the last quadrennium, CIC-P supervised about 1000 protocols, of 
which 2/3 were therapeutic and 1/3 on physiopathology. 25% of protocols con-
ducted in CIC-P were translational in collaboration with INSERM units, 20% were 
for rare diseases, 35% were funded by industry and 36% by the PHRC (Academic 
funding). The AP-HP (Academic Hospitals of Paris Area) is the major sponsor in 
France and one of the first in Europe, with 500 clinical trials enrolling more than 
17,000 patients in 2010. Despite this development, the number of CT submis-
sions to ANSM (French Regulatory Agency) decreased from 1,000 in 2008 to 895 in 
2012. ANSM approuved 705 protocols in 2012 versus 790 in 2008. cOnclusiOns: 
Despite appropriate structures and willingness to encourage scientific produc-
tion, clinical trails remain underexploited due to different causes which need to 
be deeply evaluated.
HealTH care use & Policy sTudies – Health Technology assessment  
Programs
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assessmenT?
Heemstra L.1, Purchase J.L.2, Van Engen A.1
1Quintiles Consulting, Hoofddorp, The Netherlands, 2Quintiles Consulting, Reading, UK
Objectives: In March, the National Institute for Health and Care Excellence (NICE) 
revealed their plans to implement Value Based Assessment (VBA) in their Technology 
Appraisal process: VBA will replace NICE’s end-of-life criteria. Instead wider soci-
etal impact (WSI) and burden of illness (BOI) will be systematically included in the 
assessment through absolute and proportional Quality Adjusted Life Year (QALY) 
shortfall. However, it is unclear whether these elements will impact NICE’s recom-
mendations. MethOds: The BOI and WSI for the 26 examples provided by NICE 
was compared with an average displaced treatment in the NHS. Assuming that both 
elements were weighted equally, an average QALY shortfall rating was calculated. 
This was then transformed into a hypothetical willingness to pay (WTP) threshold 
ranging from £20,000 for the drug with the lowest rating to £50,000 per QALY for 
the drug with the highest rating. The hypothetical WTP was compared with the 
most plausible ICER and recommendation from NICE. Results: Multiple Sclerosis, 
rheumatoid and psoriatic arthritis, as well as oncology indications were associated 
with a high BOI/WSI. Six of the 26 examples had higher most plausible ICERs than 
the estimated threshold. Two of these six were still recommended using end-of-
life criteria (metastatic melanoma and mCRPC), whereas the remainder were not 
recommended by NICE. Three of the 26 examples had ICERs below the estimated 
WTP threshold but higher than £30,000, and were still recommended. All of these 
recommendations mentioned additional value elements such as innovation, end-of-
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life criteria or even QoL impact on family. cOnclusiOns: This analysis presented 
a possible scenario for the implementation of VBA. None of the drugs with a nega-
tive recommendation would get a positive recommendation under this scenario. 
The products at most risk are those currently accepted using end-of-life criteria. 
However, how the new value elements will be weighted has yet to be determined.
PHP195
THe evoluTion oF inTernaTional reFerence Pricing: an analysis oF  
39 counTries
Lockwood C., Marinoni G., Ando G.
IHS, London, UK
Objectives: To characterise country-level changes to international reference 
pricing (IRP) policy frameworks across 39 markets, and understand how coun-
tries amend this tool. MethOds: Qualitative interviews were conducted with 50 
stakeholders across 39 markets, representing 37 payers or payer influencers and 13 
industry stakeholders. These interviews focused on country-level IRP methodology, 
both past and present. Extensive secondary research of government websites and 
existing literature was also conducted. A qualitative and semi-quantitative analysis 
of these findings was undertaken to identify key trends in how IRP has been modi-
fied as a policy tool since implementation. Results: Of the markets considered, 
IRP has remained comparatively stable – in terms of both the countries comprising 
the reference basket and the underlying formula for determining the reference price 
remaining unchanged – in just under one-third of the 39 markets. In contrast, just 
over one-third of these markets have modified their IRP baskets to include one or 
more additional countries with the objective of lowering prices. A smaller number 
have made substantive changes to the IRP formula itself, notably with four markets 
transitioning from taking the average price of their basket as a reference to either 
taking the average of the three lowest or taking the lowest. cOnclusiOns: IRP 
serves as a dynamic policy tool, changing to reflect individual country circum-
stances and broader policy reform over time. While a number of markets have 
maintained a stable IRP regime since inception, a larger number have made some 
changes, the most common being to add one or more markets to the reference 
basket. Although changes to IRP are mostly concentrated in Eastern European mar-
kets, as well as Western European markets most impacted by the recent economic 
crisis, the present study also suggests that there is considerable variation across 
geographies and time in how countries adapt their use of IRP.
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making sense oF nice’s ‘new’ mTa and sTa Process guide: a narraTive 
synTHesis
Urbich M., Mildred M.
Boehringer Ingelheim Ltd, Bracknell, UK
Objectives: NICE’s guides to the process of Multiple Technology Appraisals (MTA) 
and Single Technology Appraisals (STA) provide a valuable source of information 
to enable stakeholders to engage in Health Technology Appraisals (HTAs). NICE 
recently conducted a review of the process guides which has implications for all 
stakeholders involved with MTAs and STAs. The objective of this analysis was to 
identify the number and type of amendments within the guides in order to high-
light the most important changes for consultees and commentators. MethOds: 
Narrative synthesis was used to systematically identify, classify and explore the 
impact of the proposed amendments to the MTA and STA process guides. The 
hypothesis was that the amalgamation of the MTA and STA guides would simplify 
both TA processes whilst increasing rigour and transparency. Sources of reference 
were the draft of the new process guide, the NICE Senior Management Team Board 
Cover Paper, and the 2009 MTA and STA process guides. Results: Amendments 
were classified as relating to the process itself (26%), data and confidential infor-
mation (44%), terminology (7%), and others (22%). Of the 27 amendments to the 
MTA and STA process guides, 4 (15%) were identified as major amendments which 
warrant specific appreciation. Major amendments included: (1) the STA decision 
problem meeting moving to after the Department of Health referral; (2) stricter rules 
around the marking of confidential information; (3) full publication of MTAs; and 
(4) MTAs now have the opportunity to go straight to Final Appraisal Determination 
(FAD) following the first committee meeting. cOnclusiOns: The draft process 
guide suggests that the new MTA and STA processes will foster greater engage-
ment between stakeholders early on, increase transparency, and enable patients 
to have quicker access to innovative medicines which are able to go straight to FAD.
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meTHodological requiremenTs regarding qualiTy oF liFe 
measuremenT in THe early assessmenT oF BeneFiT in germany
Blome C., Augustin M., Lohrberg D.
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Objectives: In Germany, an early assessment of benefit (EAB) is required for new 
medicines since January 2011. The pharmaceutical manufacturer submits a dossier 
on additional benefit over comparative treatment which is subsequently evaluated 
by the Institute for Quality and Efficiency in Health Care (IQWiG). Stakeholders can 
comment on the evaluation in a formal comments procedure. The final decision 
on additional benefit is made by the Federal Joint Committee (G-BA); it provides the 
basis for price negotiations between manufacturer and statutory health insurance 
funds. Quality of life (QoL) is one of four criteria for benefit evaluation. This qualita-
tive study aimed to determine methodological requirements for QoL measurement 
in the German EAB. MethOds: A qualitative content analysis according to Mayring 
was conducted. Documents of all EABs completed until December 2013 (including 
dossier, IQWiG evaluation, protocol of the oral hearing, and G-BA decision) were 
searched for the term QoL or synonyms. Relevant passages were extracted and 
reduced to key content by two researchers independently. On the basis of subse-
quent consensus building, recurring themes of the term’s usage in the EAB process 
were identified. Results: In the 66 early assessments of benefit included in the 
analysis, a range of methodological requirements regarding QoL assessment, analy-
sis, and interpretation emerged. Dominant topics included: the appropriate level of 
disease-specificity of QoL instruments; required evidence on an instrument’s valid-
ity and on the validity of a minimal important difference; appropriate duration of 
QoL assessment; consequences of potential bias due to unblinded study design or 
missing data; interpretation of results that differed between subscales of an instru-
ment; non-acceptance of surrogate endpoints for QoL. cOnclusiOns: Evidence 
on QoL can have high impact on the additional benefit determined by the G-BA. 
Therefore, QoL assessment and analysis in clinical studies that shall enter benefit 
dossiers should confirm with a range of methodological requirements.
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exPloring THe Flaws in cosT-eFFecTiveness models THaT lead To 
rejecTion oF nice suBmissions
Griffiths E.A., Hendrich J.
PAREXEL, London, UK
Objectives: New health technologies are required to demonstrate both clinical and 
cost-effectiveness before recommendation by the National Institute for Health and 
Care Excellence (NICE) for reimbursement in England; however, a large proportion 
of submissions are rejected due to non-robust economic analysis. Published NICE 
guidance includes a comprehensive critique of submitted economic evidence so, to 
help inform future submissions, we assessed the flaws in cost-effectiveness models 
leading to rejection by NICE. MethOds: All NICE single technology appraisals from 
January 2006 to May 2014 were included in the analysis. Multiple technology apprais-
als, resubmissions, vaccination programmes, requests for advice, and submissions 
where an incremental cost-effectiveness ratio (ICER) could not be determined were 
excluded. Recommendations and reasoning across decisions were extracted, with 
a focus on the critique of the economic evidence. Results: 121 NICE submissions 
met the inclusion criteria, 28 (19.8%) of which were rejected. Non-robust economic 
analysis was one of the listed reasons for rejection in 75.0% (21) of cases, and in all 
cases where the submitted ICER was below the £30,000 cost-effectiveness thresh-
old. Within these submissions, the key drivers behind rejection due to non-robust 
cost-effectiveness modelling were: a high level of uncertainty in inputs (leading to a 
sensitive or unreliable ICER) (in 90.5% of cases); mishandling of data (e.g., overstated 
treatment effect or failure to account for adverse events) (85.7%); misalignment to 
the reference case (e.g., inappropriate comparator or weak methodology) (38.1%); 
and unrealistic assumptions (38.1%). cOnclusiOns: Non-robust economic analysis 
is one of the main reasons behind rejection of NICE submissions, largely due to high 
uncertainty, or selective use of data to favor the health technology being appraised. 
Early modelling may allow manufacturers to identify and address sources of uncer-
tainty or weakness early in the clinical development process, in order to construct 
a convincing and robust economic argument ahead of reimbursement submission.
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is iT PossiBle To PredicT THe markeT access oF a new PHarmaceuTical 
in germany? a sysTemaTic evaluaTion oF Federal joinT commiTTee 
decisions on early BeneFiT assessmenTs according To THe german 
law For reForming THe markeT oF PHarmaceuTicals
Schwander B.1, Banz K.2, Kaier K.3, Walzer S.4
1AHEAD GmbH, Loerrach, Germany, 2Outcomes International, Basel, Switzerland, 3University 
of Freiburg, Freiburg, Germany, 4MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, 
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Objectives: As of 1st January 2011 the German drug market is regulated by the 
act of the reorganization of the pharmaceutical market (AMNOG). Since then the 
normal procedure for reimbursement of a new pharmaceutical is an early benefit 
assessment by the joint federal committee (G-BA) which determines one of six 
additional benefit levels. According to AMNOG any specification of the reimburse-
ment price shall be based on the outcomes of the early benefit assessment. Hence 
this assessment takes a key role for market access of a new drug in Germany which 
poses the question whether it is possible to predict the level of additional benefit 
that will be established by the G-BA. MethOds: In order to evaluate a possible 
predictor of G-BA decisions, the ‘evaluation of pharmaceutical innovations (EVITA)’ 
score was calculated and retrospectively compared with 40 published G-BA deci-
sions. The EVITA algorithm evaluates a new compound for a given indication and in 
relation to a relevant comparator on the basis of randomized controlled trial (RCT) 
evidence. EVITA translates the RCT outcomes on the therapeutic benefit and risk 
profile into rating points, which are expressed as a total EVITA score. Results: 
Univariate ordinary least squares and ordered logit regression analyses show sta-
tistically significant correlations between EVITA scores and the G-BA additional 
benefit levels. Moreover, for the prediction of an additional benefit level of at least 
‘minor’, an EVITA score cutpoint of ≥ 3 is associated with a sensitivity of 100% and 
a specificity of 80%. For the prediction of an additional benefit level of at least ‘con-
siderable’, an EVITA score cutpoint of ≥ 7.5 is associated with a sensitivity of 100% 
and a specificity of 93.1%. cOnclusiOns:  The present investigation indicates that 
the EVITA score may have the potential for the prediction of G-BA decisions related 
to AMNOG early benefit assessments.
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selecTion oF ToPics For nice TecHnology aPPraisal 2005-2011: wHaT 
maTTers mosT?
Ward D.J.1, Shiyka A.2, Fellows R.1
1NIHR Horizon Scanning Centre, Birmingham, UK, 2University of Birmingham, Birmingham, UK
Objectives: The National Institute for Health and Care Excellence (NICE) under-
takes appraisals of selected health technologies, and those judged to be cost-
effective must be funded for use on the National Health Service in England and 
Wales. Obtaining a positive appraisal decision is therefore important to commer-
cial developers seeking market access, who require consistent application of topic 
selection criteria (which were amended in 2009). We sought to establish which 
characteristics of drugs or their indications were most important in the decision 
to undertake an appraisal. MethOds: All marketing authorisations (MAs) granted 
